BOSTON--Mosaic Technologies announced that it has granted a license and option relating to its patented Bridge amplification technology to Affymax Technolo gies, a wholly owned subsidiary of Glaxo Wellcome. The platform has broad applications in genomics-based drug development and pharmacogenomics, Mosaic said. Bridge amplification helps reduce time and expense by defining the genomic component and targeting the appropriate patient population, the company claimed.
Mosaic Licenses DNA Bridge Technology to Affymax Technologies
Dec 18, 1998